Minority News
The world you see depends upon the news you get. ®
April 16, 2024
ERI Receives Highest Customer Rating Score in Compliance Standards’ 2024 ITAD Vendor Reputation Survey   •     •   Idaho’s Largest Community College, the College of Western Idaho, Selects the YuJa Enterprise Video Platform as All-In-One   •     •   Applications Open for the U.S. Naval Sea Cadet Corps 2024 International Exchange Program   •     •   University of Phoenix Celebrates Faculty Thought Leadership Producing 1,240 Instances of Scholarship in 2023   •     •   EIN and the DriveH2 Movement Shine Brightly at This Year’s ‘Sonic Desert’ Party at Coachella   •     •   NGS Becomes an Authorized National Aspire® Dealer   •     •   Paralyzed Veterans of America Celebrates Women Veterans, Accessibility Changemakers at Igniting Change Gala   •     •   Solis Mammography and Northwest Healthcare Announce Strategic Joint Venture to Enhance Women's Health in the Tucson Market   •     •   Measles is Back Thanks to Vaccination Backlash, Notes AHF   •     •   Carings Appoints Tech Executive Tracey Zhen as Chief Executive Officer   •     •   Sanofi Canada invests $180M CAD to build and update infrastructure to minimize environmental footprint at its Toronto Campus by   •     •   MAKING A SPLASH: APEX SOCIAL CELEBRATES CAREGIVERS WITH SURF, SAND, AND SERVICE   •     •   Glaukos Announces the Release of its 2023 Sustainability Report   •     •   Otipemisiwak Métis Government responds to Budget 2024   •     •   Montrose Environmental Group Announces Public Offering of Shares   •     •   Walmart Collaboration with The Jessica Simpson Collection Brings Boho-Chic to its Growing Fashion Assortment   •     •   Op-Ed: When Maternal Health Goes Wrong   •     •   Our Military Kids® Presents Courageous Kids Contest Winners   •     •   New MPP tracker reveals heavy industry transition has started but needs to accelerate sevenfold to meet 2030 climate targets   •     •   agilon health Sets Date to Report First Quarter 2024 Financial Results   •  
HOME SEARCH SUBSCRIBE CONTACT

Novel Assay for Early Detection of Ovarian Cancer From Mercy BioAnalytics Significantly Outperforms CA125 in New Research Presen

NATICK, Mass. , May 27 /Businesswire/ - Mercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsies for the early detection of cancer, today announced that the Mercy Halo Ovarian Cancer (OC) assay substantially outperformed CA125 when distinguishing patients with early-stage high-grade serious ovarian cancer (HGSOC) from women with benign conditions in a new study to be presented next week at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting. The assay uses a novel method of analyzing biomarkers based on individual extracellular vesicles (EVs).

“These preliminary data suggest this approach may detect all stages of ovarian cancer with high sensitivity at a very high specificity and works equally well in both plasma and serum. Mercy’s assay shows promise in improving on CA125 by distinguishing stage I/II cancer from benign ovarian tumors and could have clinical utility for both early detection and surgical referral recommendation for benign and malignant ovarian tumors,” said Christine D. Berg, M.D., retired Chief, Early Detection Research Group, National Institutes of Health.

The study, titled “Extracellular vesicle-based biomarker assay for the detection of early-stage ovarian cancer,” will be presented on Saturday, June 4, 2022, at ASCO by Daniel Gusenleitner, Ph.D., Head of Computational Biology for Mercy Bioanalytics (Abstract #5542).

The study found that the Mercy Halo OC assay:

HGSOC is the most aggressive of all ovarian cancers and accounts for up to 70 percent of all ovarian cancer cases. Nearly 50 percent of ovarian cancer is detected at stage III or stage IV with poor survival outcomes. Current surveillance methods, including CA125, a current standard of care for ovarian cancer diagnosis, and ultrasound, are not effective enough at detecting early-stage disease. Emerging methods for early cancer detection rely primarily on tumor DNA circulating in blood (ctDNA), which is scarce in early-stage cancers, costly to measure, and not reliably obtained from tumors that are not well vascularized.

The novel Mercy Halo technology enables simultaneous detection of multiple cancer-related biomarkers co-localized on the surface of individual tumor-derived extracellular vesicles, which are abundant in circulation and can be readily measured. The Mercy Halo OC assay is designed to detect stage I/II ovarian cancer and to distinguish cancer from benign conditions.

“Too many women today suffer, and ultimately lose their lives, as a result of the late detection of ovarian cancer. We are encouraged by the data of our most recent study comparing the Mercy Halo Ovarian Cancer assay to CA125 in detecting early-stage ovarian cancer and distinguishing it from benign disease,” said Paul Blavin, Chief Executive Officer of Mercy BioAnalytics. “Our unique approach, focused on co-localization to interrogate single extracellular vesicles, has important advantages over current early cancer detection methods, and our work thus far has fueled our passion for relieving suffering and saving lives through the early detection of cancer. We look forward to expanding our studies of the Mercy Halo Ovarian Cancer assay to include average risk, asymptomatic women who might benefit from an improved ovarian cancer screening paradigm.”

ABOUT MERCY BIOANALYTICS, INC.

Mercy BioAnalytics, Inc. is on a mission to relieve suffering and save lives through the early detection of cancer. Early-stage cancer is difficult to detect, but when found, is more often amenable to curative therapy. The patented Mercy Halo liquid biopsy platform utilizes biomarker co-localization to interrogate highly abundant blood-based extracellular vesicles that carry unique cancer signatures from their parent cells. The Mercy Halo platform is designed to detect stage I cancer, when it is most treatable, and enhance the quality of life for cancer patients and their families. Mercy’s initial focus is the early detection of ovarian and lung cancers. Ovarian cancer, the most lethal gynecological cancer, typically goes undetected until it is too late to cure. Lung cancer, the number-one cancer killer, takes more lives than breast, prostate and colorectal cancers combined. For additional information, please visit https://www.mercybio.com.